



The compilation of presentations is for educational purposes only. Copies of presentations obtained through the hyperlinks are live the day of the presentation and **per the meeting’s guidelines, the hyperlink links to either the Pfizer Conference Publications Portal or the conference website for obtaining the presentation. Copies of presentations obtained through hyperlinks are for personal use only and may not be reproduced without permission from the conference and the author of those presentations.** All copyrights protected by law. Solely for non-commercial use.

# Pfizer/Alliance-Sponsored Poster Presentations

## Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile

Saturday, June 38:00 AM – 11:00 AM (CDT)

EnzalutamidePresentation 5026

Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA)

Ross A  
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

[View Presentation](#)

RelugolixPresentation 5078

Assessing racial differences in time to treatment escalation following androgen-deprivation therapy among veterans with prostate cancer

Friedrich N  
Presentation is supported by Myovant and Pfizer Alliance.

[View Presentation](#)

TalazoparibPresentation 5053

Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study

Azad A

[View Presentation](#)

TalazoparibPresentation 5056

Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Azad A

[View Presentation](#)

Poster Session: Genitourinary Cancer—Kidney and Bladder

Saturday, June 3

8:00 AM – 11:00 AM (CDT)

Avelumab

Presentation 4567

Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC)

Moon HH

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in US and Canada.*

[View Presentation](#)

Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Saturday, June 3

8:00 AM – 11:00 AM (CDT)

PF-07799933

Presentation TPS3164

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations

Beck JT

[View Presentation](#)

Poster Session: Developmental Therapeutics—Immunotherapy

Saturday, June 3

8:00 AM – 11:00 AM (CDT)

PF-07257876

Presentation 2529

Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors

Carneiro BA

[View Presentation](#)

# Pfizer-Sponsored Oral Presentation

## Oral Abstract Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Saturday, June 3

1:15 PM – 4:15 PM (CDT)

Elranatamab

Presentation 8008  
3:39 PM - 3:51 PM CDT

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies

Nooka AK

View Presentation

# Pfizer-Sponsored Poster Discussions

## Poster Discussion Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Saturday, June 3 (Poster Session)

8:00 AM – 11:00 AM (CDT)

Saturday, June 3 (Discussion Session)

1:15 PM – 2:45 PM (CDT)

PF-07220060

Presentation 3009

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy

Yap TA

View Presentation

PF-07104091

Presentation 3010

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer

Yap TA

View Presentation

PF-07284892

Presentation 3020

A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors

Drilon A

View Presentation

---

## Poster Discussion Session: Genitourinary Cancer—Prostate, Testicular, and Penile

---

Saturday, June 3 (Poster Session)	8:00 AM – 11:00 AM (CDT)
Saturday, June 3 (Discussion Session)	1:15 PM – 2:45 PM (CDT)

---

<b>Talazoparib</b>	<b>Presentation 5013</b>
--------------------	--------------------------

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)

Agarwal N

[View Presentation](#)

## Pfizer/Alliance-Sponsored Poster Presentations

---

### Poster Session: Melanoma/Skin Cancers

---

Saturday, June 3	1:15 PM – 2:45 PM (CDT)
------------------	-------------------------

---

<b>Encorafenib and Binimetinib</b>	<b>Presentation 9531</b>
------------------------------------	--------------------------

Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI)

Schadendorf D

[View Presentation](#)

---

<b>Avelumab</b>	<b>Presentation 9537</b>
-----------------	--------------------------

Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database

Blom A  
*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in US and Canada.*

[View Presentation](#)

---

### Poster Session: Health Services Research and Quality Improvement

---

Saturday, June 3	1:15 PM – 2:45 PM (CDT)
------------------	-------------------------

---

<b>Biosimilars</b>	<b>Presentation 6613</b>
--------------------	--------------------------

An assessment of the provider financial risk impacts of adoption of biosimilars in the Medicare Oncology Care Model

Roth JA

[View Presentation](#)

Elranatamab

Presentation 6618

An indirect comparison of eranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) versus real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)

Costa LJ

View Presentation

Pfizer/Alliance-Sponsored Poster Discussions

Poster Discussion Session: Genitourinary Cancer—  
Kidney and Bladder

Saturday, June 3 (Poster Session)8:00 AM – 11:00 AM (CDT)

Saturday, June 3 (Discussion Session)3:00 PM – 4:30 PM (CDT)

Avelumab

Presentation 4515

Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis

Powels T

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in US and Canada.*

View Presentation

Avelumab

Presentation 4516

Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial

Bellmunt J

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in US and Canada.*

View Presentation

Pfizer-Sponsored Oral Presentation

Oral Abstract Session: Genitourinary Cancer—  
Prostate, Testicular, and Penile

Sunday, June 48:00 AM – 11:00 AM (CDT)

Talazoparib

Presentation 5004  
9:12 AM - 9:24 AM (CDT)

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations

Fizazi K

View Presentation

# Pfizer-Sponsored Poster Presentations

## Poster Session: Breast Cancer—Metastatic

Sunday, June 4

8:00 AM – 11:00 AM (CDT)

PF-07248144

Presentation 1054

First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors

Sommerhalder D

[View Presentation](#)

ARV-471

Presentation TPS1121

TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer

Layman R

*Presentation is supported by Pfizer and ARVINAS.*

[View Presentation](#)

ARV-471

Presentation TPS1122

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Camponé M

*Presentation is supported by Pfizer and ARVINAS.*

[View Presentation](#)

## Poster Session: Lung Cancer—Non-Small Cell Metastatic

Sunday, June 4

8:00 AM – 11:00 AM (CDT)

Lorlatinib

Presentation 9063

Management of patients with *ALK*-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial

Bauer T

[View Presentation](#)

# Pfizer-Sponsored Poster Discussions

## Poster Discussion Session: Breast Cancer—Metastatic

Sunday, June 4 (Poster Session)	8:00 AM – 11:00 AM (CDT)
Sunday, June 4 (Discussion Session)	11:30 AM – 1:30 PM (CDT)

**Palbociclib****Presentation 1018**

First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program

Carola E

[View Presentation](#)

## Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic

Sunday, June 4 (Poster Session)	8:00 AM – 11:00 AM (CDT)
Sunday, June 4 (Discussion Session)	4:30 PM – 6:00 PM (CDT)

**Encorafenib and Binimetinib****Presentation 9018**

Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with *BRAF* V600E-mutant (*BRAF*<sup>V600E</sup>) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study

Riely G

[View Presentation](#)

# Pfizer-Sponsored Poster Presentations

## Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Monday, June 5	8:00 AM – 11:00 PM (CDT)
----------------	--------------------------

**Elranatamab****Presentation 8039**

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study

Mohty M

[View Presentation](#)

**Elranatamab****Presentation 8040**

Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3

Raje N

[View Presentation](#)



Elranatamab

Presentation 8044

Identification of cytokines associated with response and cytokine release syndrome:  
Analysis of MagnetisMM-3 cohort A

Quach H

View Presentation

Elranatamab

Presentation 8045

Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A

Bahlis NJ

View Presentation

Elranatamab

Presentation TPS8065

MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

Grosicki S

View Presentation

Elranatamab

Presentation TPS8066

MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma

Mateos Manteca M

View Presentation

## Poster Session: Gastrointestinal Cancer—Colorectal and Anal

Monday, June 5

8:00 AM – 11:00 AM (CDT)

Encorafenib and Binimetinib

Presentation TPS3627

BREAKWATER: An open-label, multicenter, randomized phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Kopetz S

View Presentation



# Pfizer-Sponsored Oral Presentation

## Oral Abstract Session: Sarcoma

Monday, June 511:30 AM – 2:30 PM (CDT)

**TTI-621****Presentation 11508**  
*1:54 PM - 2:06 PM CDT*

Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort

Movva S

[View Presentation](#)

# Pfizer-Sponsored Poster Presentation

## Poster Session: Pediatric Oncology

Monday, June 51:15 PM – 4:15 PM (CDT)

**Palbociclib****Presentation TPS10069**

Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma

Laetsch T

[View Presentation](#)

# Publication Only

Encorafenib and Binimetinib

e21506

Patient Characteristics and Treatment Patterns in BRAF-mutated Unresectable or Metastatic Melanoma in the United States: A Snapshot from Real-World Data

Mesana L

Elranatamab

e20021

Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1

Tomasson MH

Elranatamab

e18826

Real-World Treatment Patterns of Triple-Class Refractory (TCR) Multiple Myeloma (MM) Across the United States (US), Canada, and Western Europe: A Retrospective Chart Study

Guillaume X

Elranatamab

e18827

Treatment Patterns of Triple-Class Refractory (TCR) Multiple Myeloma (MM) Across the United States (US), Canada, and Western Europe: A Real-World Observational Chart Review Study

Goyal RK

Elranatamab

e20017

Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3

Larson S

Elranatamab

e20038

A matching-adjusted indirect treatment comparison of elranatamab in patients with triple-class exposed relapsed/refractory multiple myeloma: Comparisons with belantamab mafodotin, selinexor plus dexamethasone, and real-world physician’s choice of treatment

Hlavacek P

# Publication Only Cont'd

Enzalutamide

e17081

Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume

Freedland SJ  
*Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.*

Enzalutamide

e17085

Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry

Shevrin D  
*Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.*

Axitinib

e16553

Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States

Zakharia Y

Avelumab

e16559

The evolution of treatment patterns in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) and clinical outcomes: Results of a longitudinal observational cohort study in England

Mahmoudpour SH  
*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in US and Canada.*